Skip to main content


Prof. Mark Cauldfield, Device-based therapy for hypertension

Prof. Mark Cauldfield
Prof. Mark Cauldfield

Date: Wed 26 Jun 2013, 15:00 - 16:00

Location: The People's Palace - PP2

Prof. Mark Cauldfield, Director of the William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary, University of London

SEMS/IoB Seminar Series
Coffee/tea/biscuits provided after the seminar

There will be 1.5 billion people worldwide with hypertension in 2025. A proportion of those remain uncontrolled and may be resistant to treatment. Device based therapy for proven resistant hypertension is a new procedure with an emerging evidence base of effectiveness and safety. Our research on renal denervation in 2010 allowed us to lead the Joint UK Societies’ Consensus Statement on renal denervation was prepared to support the National Institute of Health and Clinical Excellence Interventional Procedure Guidance on Renal Denervation (NICE IP418) by representatives of key stakeholder societies. In these recommendations we proposed that we rely upon the current evidence-base to select patients with resistant hypertension who may be eligible for this therapy. We have now assisted with adoption of this technology into the NHS in the UK. There are now over 80 such devices in development or under trial worldwide.

Updated by: Jonathon Hills